<DOC>
	<DOCNO>NCT02684838</DOCNO>
	<brief_summary>This prospective , observational registry patient prescribe Gliadel Wafer physician part usual care .</brief_summary>
	<brief_title>Vigilant ObservatIon GlIadeL WAfer ImplaNT Registry</brief_title>
	<detailed_description>This prospective , observational registry patient prescribe Gliadel Wafer physician part usual care . Data collect safety effectiveness treatment Gliadel Wafer perioperatively ongoing regular office visit 3-years . Patients enrol registry ask complete questionnaire ( Functional Assessment Cancer Therapy-Brain [ FACT-Br ] ) well-being clinician complete Karnofsky Performance Status ( KPS ) office visit .</detailed_description>
	<mesh_term>Carmustine</mesh_term>
	<criteria>1 . Signed informed consent , patient legally acceptable representative , obtain registryrelated activity undertake . The informed consent must sign within 14 calendar day surgery . 2 . Male female patient , great equal 18 year age age majority state residence . 3 . Patients plan receive Gliadel Wafer , already receive Gliadel Wafer sign consent enroll registry within 14 calendar day surgery treatment central nervous system ( CNS ) tumor ( ) , currently enrol another study receive Gliadel Wafer . 4 . Signed release form , patient legally acceptable representative , permit abstraction patient 's medical record Baseline participation registry . 1 . The patient enrol interventional clinical trial , treatment CNS tumor ( ) manage protocol exclude Gliadel Wafer treatment . 2 . Any abnormality medical condition , discretion Investigator , may put patient increase risk participate registry . 3 . Any reason , Investigator 's opinion , make patient unsuitable participate registry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Gliadel , Carmustine wafer implant</keyword>
</DOC>